Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Completes $270 M Second Offering



AITHERSBURG, Md.--Gene Logic announced that it has completed a $270 million follow-on offering of 4.83 million shares of common stock at $56 per share. The total includes the exercise of the underwriters’ overallotment option of 630,000 shares, 150,000 of which were sold by certain stockholders of the company. The gross proceeds to Gene Logic from the offering were $262 million. Net proceeds will be used to fund product and technology development, expand database product marketing efforts, and provide working capital for general corporate purposes, including possible acquisitions. Mark Gessler, Gene Logic’s president and chief operating officer said, "The completion of this offering creates a very strong foundation for future growth of the company, further development of the GeneExpress database, and expansion of the marketing and sales organization."

Filed under

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.